According to the study, the country’s overreliance on pharmaceutical ingredients manufactured in overseas factories threatens national security and health.
A representative from Clarivate explains how supply chain vulnerabilities can hurt stakeholders, including patients—and how one solution can close the gap.
A leader from the company says to ensure medicines keep reaching the patients that need them, the industry must revamp outdated technologies and techniques.
This month’s roundup of new excipients, manufacturing sites, partnerships, and other items includes news from DFE Pharma, Vetter, and other notable firms.
As the industry begins coming out of the COVID-19 pandemic, experts advise keeping an eye on growth and partnership opportunities in the US pharma market.
The virtual event (scheduled June 22-24) will feature presentations from Bayer, Merck, GSK, Novartis, Takeda, FDA, WHO, and other notable organizations.
A leader from the supply-chain specialist explains vulnerabilities and challenges unique to pharma, and how professionals can safeguard and streamline.
Three leaders from pharma ingredients and innovation firm Lonza share views on challenges and opportunities likely to face the industry in coming months.
According to an executive from the drug development services company, pharma professionals should pay close attention to supply chain continuity and safety in the coming year.
The company has received a $500,000 grant from the COVID-19 Therapeutics Accelerator to develop manufacturing processes for the antiviral drug remdesivir.
A leader from the scientific software provider discusses the most challenging obstacles in the pharma supply chain, and solutions that can conquer them.
The bipartisan bill calls for an assessment of the country’s pharma supply chain, including potential vulnerabilities and impact of foreign manufacturing.
The ninth annual event, taking place in Boston mid-November, will feature industry professionals addressing manufacturing practices, regulatory updates and market trends.
After the Indian government moved to limit the export of APIs, an Indian export association says fear is spreading amongst European businesses over supply.
With the supply of certain APIs limited by the spread of the virus, Indian government orders restrictions on the export of ingredients and formulations.
Driven by market demand, De Dietrich develops an API production set that enables continuous manufacturing of molecules that require exothermic chemical reactions.
As part of an evaluation of its manufacturing network, the company concluded that the Ringaskiddy production building was no longer a competitive, long-term option.
API recalls have sparked discussion on the development of impurities during manufacturing and the ways in which risks can be mitigated, according to an industry expert.
The acquisition of two migraine therapies from Dr Reddy’s has been completed by Upsher-Smith, adding different drug delivery treatment options to its migraine product portfolio.
